Aurora A Kinase in Complex with JNJ-7706621 in Space Group P6122

Experimental Data Snapshot

  • Resolution: 2.15 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.210 
  • R-Value Observed: 0.211 

wwPDB Validation   3D Report Full Report

This is version 1.0 of the entry. See complete history


Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.

Janecek, M.Rossmann, M.Sharma, P.Emery, A.Huggins, D.J.Stockwell, S.R.Stokes, J.E.Tan, Y.S.Almeida, E.G.Hardwick, B.Narvaez, A.J.Hyvonen, M.Spring, D.R.McKenzie, G.J.Venkitaraman, A.R.

(2016) Sci Rep 6: 28528-28528

  • DOI: https://doi.org/10.1038/srep28528
  • Primary Citation of Related Structures:  
    5DN3, 5DNR, 5DOS, 5DPV, 5DR2, 5DR6, 5DR9, 5DRD, 5DT0, 5DT3, 5DT4

  • PubMed Abstract: 

    The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progression via two distinct mechanisms. Following activation loop autophosphorylation early in mitosis when it localizes to centrosomes, AURKA is allosterically activated on the mitotic spindle via binding to the microtubule-associated protein, TPX2. Here, we report the discovery of AurkinA, a novel chemical inhibitor of the AURKA-TPX2 interaction, which acts via an unexpected structural mechanism to inhibit AURKA activity and mitotic localization. In crystal structures, AurkinA binds to a hydrophobic pocket (the 'Y pocket') that normally accommodates a conserved Tyr-Ser-Tyr motif from TPX2, blocking the AURKA-TPX2 interaction. AurkinA binding to the Y- pocket induces structural changes in AURKA that inhibit catalytic activity in vitro and in cells, without affecting ATP binding to the active site, defining a novel mechanism of allosteric inhibition. Consistent with this mechanism, cells exposed to AurkinA mislocalise AURKA from mitotic spindle microtubules. Thus, our findings provide fresh insight into the catalytic mechanism of AURKA, and identify a key structural feature as the target for a new class of dual-mode AURKA inhibitors, with implications for the chemical biology and selective therapeutic targeting of structurally related kinases.

  • Organizational Affiliation

    Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Old Addenbrooke's Site, Cambridge CB2 1GA.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Aurora kinase A273Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for O14965 (Homo sapiens)
Explore O14965 
Go to UniProtKB:  O14965
PHAROS:  O14965
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO14965
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on SKE

Download Ideal Coordinates CCD File 
B [auth A]4-({5-amino-1-[(2,6-difluorophenyl)carbonyl]-1H-1,2,4-triazol-3-yl}amino)benzenesulfonamide
C15 H12 F2 N6 O3 S
Binding Affinity Annotations 
IDSourceBinding Affinity
SKE BindingDB:  5DT0 Kd: 250 (nM) from 1 assay(s)
IC50: 11 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.15 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.210 
  • R-Value Observed: 0.211 
  • Space Group: P 61 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 81.741α = 90
b = 81.741β = 90
c = 164.612γ = 120
Software Package:
Software NamePurpose
XDSdata reduction
Aimlessdata scaling
AutoPROCdata reduction

Structure Validation

View Full Validation Report

Entry History & Funding Information

Deposition Data

Funding OrganizationLocationGrant Number
Wellcome TrustUnited KingdomStrategic Award 090340/Z/09/Z

Revision History  (Full details and data files)

  • Version 1.0: 2016-07-20
    Type: Initial release